合併interleukin-12及interleukin-18為基礎之免疫基因療法及抗血管生成基因療法對於大鼠神經膠質瘤的療效(1/3)
Date Issued
2004-07-31
Date
2004-07-31
Author(s)
曾勝弘
DOI
922314B002253
Abstract
This 3-year project is intended to investigate the effects of combined interleukin-12 (IL-12)-
and IL-18-based gene therapy and anti-angiogenesis gene therapy on the intracerebral gliomas in
rats. We constructed several recombinant adenoviral vectors, including Ad/IL-12, Ad/IL-18,
Ad/Endo, with the titers in the range of 1011 to 1012 pfu. Then these adenoviral vectors were used
to treat the intracerebral gliomas. All the control rats and the rats treated with Ad/IL-18 died. By
contrast, the survival rate of the rats treated with Ad/IL-12 was 50%, Ad/ME was 30%,
Ad/IL-12+Ad/IL-18 was 50%, Ad/IL-12+Ad/ME was 70%, Ad/IL-18+Ad/ME was 30%, and
Ad/IL-12+Ad/IL-18+Ad/ME was 70%. The Ad/IL-12, Ad/IL-12+Ad/IL-18, Ad/IL-12+Ad/ME,
and Ad/IL-12+Ad/IL-18+Ad/ME groups had higher survival rate than the control groups
(P<0.05). However, the Ad/IL-18, Ad/ME, Ad/IL-18+ Ad/ME groups showed no significant
difference from the control groups (P>0.05). on the other hand, Ad/IL-12+Ad/IL-18+Ad/ME
group had higher survival rate than Ad/IL-18, Ad/ME, or Ad/IL-18+Ad/ME groups (P<0.05), but
showed no difference from the Ad/IL-12, Ad/IL-12+Ad/IL-18, or Ad/IL-12+Ad/ME groups
(P>0.05). The results indicated that Ad/IL-12 alone was effective for the treatment of
intracerebral gliomas, by contrast, Ad/IL-18 had no therapeutic effect on the glioma. Combined
Ad/IL-12 and Ad/IL-18 showed no synergistic effects. Combined Ad/IL-12 and Ad/ME shoed
synergistic effects on the intracerebral gliomas, however, addition of Ad/IL-18 did not enhance
the therapeutic effects.
Subjects
glioma
immunogene therapy
anti-angiogenesis gene therapy
adenoviral vector
Publisher
臺北市：國立臺灣大學醫學院外科
Type
report
File(s)![Thumbnail Image]()
Loading...
Name
922314B002253.pdf
Size
45.17 KB
Format
Adobe PDF
Checksum
(MD5):f7ee37bb8a98c4d98c8169727c8d4f12